Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Galasko

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Annals of Neurology|February 28, 2001
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementiaV Zhukareva, V Vogelsberg-Ragaglia, V M Van Deerlin, et al.
Neurology|August 10, 2005
Rate of progression differs in frontotemporal dementia and Alzheimer diseaseK Rascovsky, D P Salmon, A M Lipton, et al.
Alzheimer Disease and Associated Disorders|January 1, 1997
A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative StudyS H Ferris, J A Mackell, R Mohs, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 15, 2005
Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementiaJ Wiltfang, P Lewczuk, P Riederer, et al.
Archives of Neurology|July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotypeD Galasko, L Chang, R Motter, et al.
Archives of Neurology|November 16, 2001
TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of GuamP Poorkaj, D Tsuang, E Wijsman, et al.
Human Molecular Genetics|August 13, 1998
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's diseaseJ C Lambert, C Berr, F Pasquier, et al.
Annals of Clinical Biochemistry|April 4, 2009
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's diseaseN A Verwey, W M van der Flier, K Blennow, et al.
Neurology|November 1, 1996
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopI G McKeith, D Galasko, K Kosaka, et al.
Neurology|March 14, 2007
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkersC F Lippa, J E Duda, M Grossman, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Annals of Neurology|February 28, 2001
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementiaV Zhukareva, V Vogelsberg-Ragaglia, V M Van Deerlin, et al.
Neurology|August 10, 2005
Rate of progression differs in frontotemporal dementia and Alzheimer diseaseK Rascovsky, D P Salmon, A M Lipton, et al.
Alzheimer Disease and Associated Disorders|January 1, 1997
A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative StudyS H Ferris, J A Mackell, R Mohs, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 15, 2005
Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementiaJ Wiltfang, P Lewczuk, P Riederer, et al.
Archives of Neurology|July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotypeD Galasko, L Chang, R Motter, et al.
Archives of Neurology|November 16, 2001
TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of GuamP Poorkaj, D Tsuang, E Wijsman, et al.
Human Molecular Genetics|August 13, 1998
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's diseaseJ C Lambert, C Berr, F Pasquier, et al.
Annals of Clinical Biochemistry|April 4, 2009
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's diseaseN A Verwey, W M van der Flier, K Blennow, et al.
Neurology|November 1, 1996
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopI G McKeith, D Galasko, K Kosaka, et al.
Neurology|March 14, 2007
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkersC F Lippa, J E Duda, M Grossman, et al.
Pageof 11